% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Flaadt:284756,
      author       = {T. Flaadt and M. Ebinger and M. Schreiber and R. L.
                      Ladenstein and T. Simon and H. N. Lode and B. Hero and M. U.
                      Schuhmann and J. Schäfer and F. Paulsen and B.
                      Timmermann$^*$ and A. Eggert and P. Lang},
      title        = {{M}ultimodal {T}herapy with {C}onsolidating
                      {H}aploidentical {S}tem {C}ell {T}ransplantation and
                      {D}inutuximab {B}eta for {P}atients with {H}igh-{R}isk
                      {N}euroblastoma and {C}entral {N}ervous {S}ystem {R}elapse.},
      journal      = {Journal of Clinical Medicine},
      volume       = {12},
      number       = {19},
      issn         = {2077-0383},
      address      = {Basel},
      publisher    = {MDPI},
      reportid     = {DKFZ-2023-02067},
      pages        = {6196},
      year         = {2023},
      abstract     = {Despite highly intensive multimodality treatment regimens,
                      the prognosis of patients with high-risk neuroblastoma
                      (HRNB) and central nervous system (CNS) relapse remains
                      poor. We retrospectively reviewed data from 13 patients with
                      HRNB and CNS relapse who received multimodal therapy with
                      consolidating haploidentical stem cell transplantation
                      (haplo-SCT) followed by dinutuximab beta ± subcutaneous
                      interleukin-2 (scIL-2). Following individual relapse
                      treatment, patients aged 1-21 years underwent haplo-SCT with
                      T/B-cell-depleted grafts followed by dinutuximab beta 20
                      mg/m2/day × 5 days for 5-6 cycles. If a response was
                      demonstrated after cycle 5 or 6, patients received up to
                      nine treatment cycles. After haplo-SCT, eight patients had a
                      complete response, four had a partial response, and one had
                      a stable disease. All 13 patients received ≥3 cycles of
                      immunotherapy. At the end of the follow-up, 9/13 patients
                      $(66.7\%)$ demonstrated complete response. As of July 2023,
                      all nine patients remain disease-free, with a median
                      follow-up time of 5.1 years since relapse. Estimated 5-year
                      event-free and overall survival rates were $55.5\%$ and
                      $65.27\%,$ respectively. Dinutuximab beta ± scIL-2
                      following haplo-SCT is a promising treatment option with a
                      generally well-tolerated safety profile for patients with
                      HRNB and CNS relapse.},
      keywords     = {central nervous system (Other) / dinutuximab beta (Other) /
                      neuroblastoma (Other) / recurrence (Other)},
      cin          = {ED01},
      ddc          = {610},
      cid          = {I:(DE-He78)ED01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:37834840},
      pmc          = {pmc:PMC10573405},
      doi          = {10.3390/jcm12196196},
      url          = {https://inrepo02.dkfz.de/record/284756},
}